论文部分内容阅读
目的探讨阿托伐他汀对急性冠脉综合征(ACS)患者血清MIF、MMP-1及hs-CRP的影响。方法 将170例冠心病患者分为2组:ACS组120例,稳定性心绞痛(SAP)组50例,另选同期40例冠状动脉造影正常者为对照组。同时随机将ACS患者分为阿托伐他汀组和常规治疗组各60例。采用酶联免疫吸附法(ELISA)测定血清MIF、MMP-1水平,用超敏乳胶增强免疫比浊法测定血清hs-CRP水平,比较各组血清MIF、MMP-1、hs-CRP水平的变化。结果ACS组血清MIF、MMP-1、hs-CRP水平显著高于SAP组和对照组(P<0.01)。阿托伐他汀组治疗后与治疗前及常规治疗组治疗后比较,血清MIF、MMP-1、hs-CRP水平明显下降(P<0.01或0.05)。结论阿托伐他汀可降低ACS患者血清MIF、MMP-1、hs-CRP水平,减少冠状动脉粥样斑块基质成分的降解和炎症反应,增强动脉粥样硬化斑块的稳定性。
Objective To investigate the effect of atorvastatin on serum MIF, MMP-1 and hs-CRP in patients with acute coronary syndrome (ACS). Methods 170 patients with coronary heart disease were divided into two groups: ACS group (120 cases), stable angina pectoris group (SAP group), and the other 40 cases of normal coronary angiography as control group. ACS patients were randomly divided into atorvastatin group and conventional treatment group of 60 cases. Serum levels of MIF and MMP-1 were measured by enzyme-linked immunosorbent assay (ELISA), serum hs-CRP level was measured by using hypersensitive latex enhanced immunoturbidimetry, and the changes of serum MIF, MMP-1 and hs-CRP levels were compared . Results Serum levels of MIF, MMP-1 and hs-CRP in ACS group were significantly higher than those in SAP group and control group (P <0.01). Serum levels of MIF, MMP-1 and hs-CRP were significantly decreased in atorvastatin group compared with before treatment and after treatment (P <0.01 or 0.05). Conclusions Atorvastatin can reduce the levels of serum MIF, MMP-1 and hs-CRP in ACS patients, reduce the degradation and inflammation of matrix components of coronary atherosclerosis and enhance the stability of atherosclerotic plaque.